All the existing ALS drugs
The charts above each show two lines, one for untreated decline and the other representing treated decline. It can be seen that the error bars overlap showing no efficacy.

                     Neuralzeta
Showing the monthly decline BEFORE starting Neuralzeta (solid black line) and the RED line showing the decline AFTER starting.  The dashed black line shows the decline extrapolated from prior to start. i.e.. what would happen if never taken Neuralzeta.

Important information

The RC Charity Group  has no connection with any other entity, charity or corporate, and has no external financial support. Being privately funded by a single person, and the public nor any ALS victim have ever been asked for money, there is no requirement to register ​​the charity and incur the associated administrative costs (Registration, trustees, auditing etc.).
The humanitarian objective is to bring a potentially new horizon to those affected by ALS (also known as MND) - irrespective of their financial status. Provided free of any charge on first come first served basis (when funds are available) to any ALS/MND victim who asks for help, has a confirmed diagnosis, informed consent, credible case history and a valid prescription.

As more than 10 years of clinical data are covered in this site, precise statistics vary at different times.
The charity states the factual data believed to be true and accurate as reported by patients observed by their neurologists, in their monthly monitoring reports. The charity makes no claims, only presents the reported efficacy evidence. 
Web sites cost money to optimise. This web site is not intended to be viewed on mobile devices.
NOTE: Nothing in this web site may be considered to be medical advice. You must always consult with your neurologist or doctor.
Web site last updated March 2024. © RC Charity 2014 - 2024.